Aelis Farma SA
AELIS.PA
| Exchange: | PA |
| Currency | Euro |
| ISIN: | FR0014007ZB4 |
| Primary Ticker: | AELIS.PA |
| Fiscal Year End: | December |
| Sector: | Healthcare |
| Industry: | Biotechnology |
| Gic Sector: | Health Care |
| Gic Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| Gic Industry: | Biotechnology |
| Gic Sub Industry: | Biotechnology |
| Description: | Aelis Farma SA, a clinical-stage biotechnology company, focuses on discovering and developing drug candidates for the treatment of central nervous system disorders. It is developing signaling-specific inhibitors of the CB1 receptors, such as AEF0117, a drug candidate, which is in Phase 2b clinical trials for the treatment of the harmful effects of excessive cannabis use; and AEF0217, a drug candidate, which is in phase I/II clinical trials to treat cognitive deficits observed in Down syndrome, as well as other cognitive impairments. The company was incorporated in 2013 and is headquartered in Bordeaux, France. |
| Address: | 146 rue Lafaurie de Monbadon, Bordeaux, France, 33 000 |
| Website: | https://www.aelisfarma.com |
| Full Time Employees: | 26 |
| Updated On: | 2024-11-03 |
Highlights
| Market Capitalization: | 47390988 |
| Market Capitalization Mln: | 47.39 |
| EBITDA: | -7554000 |
| Wall Street Target Price: | 21.3 |
| Book Value: | 0.75 |
| Earnings Share: | -0.53 |
| Most Recent Quarter: | 2024-06-30 |
| Profit Margin: | -0.65 |
| Operating Margin TTM: | -0.88 |
| Return On Assets TTM: | -0.17 |
| Return On Equity TTM: | -0.51 |
| Revenue TTM: | 10781000 |
| Revenue Per Share TTM: | 0.81 |
| Quarterly Revenue Growth YOY: | -0.27 |
| Gross Profit TTM: | 10762000 |
| Diluted Eps TTM: | -0.53 |
Valuation
| Price Sales TTM: | 4.39 |
| Price Book MRQ: | 4.76 |
| Enterprise Value: | 39890981 |
| Enterprise Value Revenue: | 5.28 |
| Enterprise Value Ebitda: | 37.90 |
Shares
| Shares Outstanding: | 13618100 |
| Shares Float: | 3049501 |
| Percent Institutions: | 0.99 |
Technicals
| Beta: | 0.08 |
| 52 Week High: | 13.6 |
| 52 Week Low: | 3.4 |
| 50 Day MA: | 5.36 |
| 200 Day MA: | 10.95 |
Earnings
| Report Date: | 2023-04-03 |
| Date: | 2023-03-31 |
| Before After Market: | After Market |
| Currency: | EUR |
| Eps Actual: | -0.28 |
| Eps Difference: | -0.28 |
| Report Date: | 2022-09-26 |
| Date: | 2022-06-30 |
| Before After Market: | After Market |
| Currency: | EUR |
| Eps Actual: | -0.93 |
| Eps Difference: | -0.93 |
| Report Date: | 2022-04-26 |
| Date: | 2022-03-31 |
| Currency: | EUR |
| Eps Actual: | -0.26 |
| Eps Difference: | -0.26 |
| Report Date: | 2022-02-03 |
| Date: | 2021-12-31 |
| Before After Market: | After Market |
| Currency: | EUR |
| Eps Actual: | -0.11 |
| Eps Difference: | -0.11 |
| Date: | 2023-03-31 |
| Eps Actual: | -1.4 |
| Date: | 2021-12-31 |
| Eps Actual: | -0.1 |